Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Subscribe To Our Newsletter & Stay Updated